Skip Navigation


Annals of Oncology Advance Access originally published online on September 21, 2009
Annals of Oncology 2009 20(12):2019-2020; doi:10.1093/annonc/mdp456
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/12/2019-a    most recent
mdp456v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vignani, F.
Right arrow Articles by Berruti, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vignani, F.
Right arrow Articles by Berruti, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen

The first 10% of the full text of this article appears below.

In a recent paper, Loriot et al. [1] explored the issue of whether carboplatin plus etoposide regimen is more active in castration-resistant prostate cancer patients with neuroendocrine differentiation as opposed to those without. In a patient population resistant to docetaxel therapy, they observed a prostate-specific antigen (PSA) response rate in . . . [Full Text of this Article]

funding

disclosure

F. Vignani1, L. Russo1, M. Tucci1, M. Motta2, G. Vellani3, M. Tampellini1, M. Papotti1, L. Dogliotti1 and A. Berruti1,*

1 Medical Oncology and Pathology Unit, Department of Clinical and Biological Science, Università di Torino, Azienda Ospedaliero Universitaria San Luigi, Orbassano
2 Pathology Unit, Ospedale Mauriziano
3 Medical Oncology, Ospedale Civile di Ivrea, Torino, Italy

* (E-mail: alfredo.berruti@gmail.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?